Annotation of the Drosophila melanogaster euchromatic genome: a systematic review

Autor: Misra S, Ma, Crosby, Christopher Mungall, Bb, Matthews, Ks, Campbell, Hradecky P, Huang Y, Js, Kaminker, Gh, Millburn, Se, Prochnik, Cd, Smith, Jl, Tupy, Ej, Whitfied, Bayraktaroglu L, Bp, Berman, Br, Bettencourt, Se, Celniker, Ad, Grey, Ra, Drysdale, Nl, Harris, Richter J, Russo S, Aj, Schroeder, Sq, Shu, Stapleton M, Yamada C, Ashburner M, Wm, Gelbart, Gm, Rubin, Se, Lewis

Publikováno v: Scopus-Elsevier
Genome Biology
Europe PubMed Central

The recent completion of the Drosophila melanogaster genomic sequence to high quality, and the availability of a greatly expanded set of Drosophila cDNA sequences, afforded FlyBase the opportunity to significantly improve genomic annotations.
Ba

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c6fc9768d10fed6c4022757f6467813e
http://www.scopus.com/inward/record.url?eid=2-s2.0-0002636459&partnerID=MN8TOARS

The safety and tolerability of alkaloids from Alstonia scholaris leaves in healthy Chinese volunteers: a single-centre, randomized, double-blind, placebo-controlled phase I clinical trial.

Autor: Gou ZP; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Zhao YL; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, People's Republic of China.; Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education; Yunnan Provincial Center for Research & Development of Natural Products; School of Chemical Science and Technology, Yunnan University, Kunming, People's Republic of China., Zou LL; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Wang Y; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Shu SQ; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Zhu XH; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Zheng L; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Shen Q; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Luo Z; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Miao J; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Wang YS; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China., Luo XD; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, People's Republic of China.; Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education; Yunnan Provincial Center for Research & Development of Natural Products; School of Chemical Science and Technology, Yunnan University, Kunming, People's Republic of China., Feng P; Institute of Drug Clinical Trials, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Publikováno v: Pharmaceutical biology [Pharm Biol] 2021 Dec; Vol. 59 (1), pp. 484-493.

[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction].

Autor: Hu C; Phase I Clinical Research Unit,West China Hospital,Sichuan University,Chengdu 610041, China; 2., Zheng J; Phase I Clinical Research Unit,West China Hospital,Sichuan University,Chengdu 610041, China; 2., Miao J; Phase I Clinical Research Unit,West China Hospital,Sichuan University,Chengdu 610041, China; 2., Liu F; Department of Nephrology,West China Hospital,Sichuan University,Chengdu 610041,China; 3., Hu TT; Department of Clinical Pharmacology,Chengdu Military Region Central Hospital,Chengdu 610083,China;4., Gu JK; The Research Center of Drug Metabolism,Jilin University,Changchun 130000,China., Shu SQ; Phase I Clinical Research Unit,West China Hospital,Sichuan University,Chengdu 610041, China; 2., Wang Y; Phase I Clinical Research Unit,West China Hospital,Sichuan University,Chengdu 610041, China; 2., Zhu XH; Phase I Clinical Research Unit,West China Hospital,Sichuan University,Chengdu 610041, China; 2., Liang MZ; Phase I Clinical Research Unit,West China Hospital,Sichuan University,Chengdu 610041, China; 2.

Publikováno v: Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition [Sichuan Da Xue Xue Bao Yi Xue Ban] 2018 Jan; Vol. 49 (1), pp. 74-80.

[Pharmacokinetics study of injected doripenemin healthy volunteers].

Autor: Liu W, Qin YP, Wang Y, Zheng J, Zhang L, Shu SQ, Miao J

Publikováno v: Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition [Sichuan Da Xue Xue Bao Yi Xue Ban] 2015 Jan; Vol. 46 (1), pp. 140-4.

Severe insulin allergy after percutaneous transluminal coronary angioplasty.

Autor: Wang C; Division of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China., Ding ZY, Shu SQ, Liu Y, Chen YC, Ran XW, An ZM, Tian HM, Tong NW, Li XJ, Yu YR

Publikováno v: Clinical therapeutics [Clin Ther] 2009 Mar; Vol. 31 (3), pp. 569-74.